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Tumor Response to Transcatheter Arterial
Chemoembolization in Recurrent
Hepatocellular Carcinoma after Living
Donor Liver Transplantation
Objective: To evaluate the tumor response and patient survival rate following
transcatheter arterial chemoembolization (TACE) in recurrent hepatocellular car-
cinoma (r-HCC) after living donor liver transplantation (LDLT). 
Materials and Methods: Twenty-eight patients with r-HCC underwent one or
more cycles of TACE after LDLT (mean, 2.5 cycles). After a mixture of iodized oil
and anti-cancer drugs was injected via the arteries feeding the tumors, these ves-
sels were embolized with a gelatin sponge. Tumor response was determined by
follow-up CT imaging on all patients four weeks after each TACE procedure.
Patient survival was calculated using the Kaplan-Meier survival curve. 
Results: After TACE, targeted tumor reduced in size by 25% or more in 19 of
the 28 study patients (67.9%). However, intrahepatic recurrence or extrahepatic
metastasis occurred in 21 of the 28 patients (75.0%) during the 3-month follow-up
period and in 26 of the 28 patients (92.9%) during the 6-month period following
TACE. Extrahepatic metastasis was noted in 18 of the 28 patients (64.3%). The
1-, 3- and 5-year survival rates following TACE were 47.9, 6.0 and 0%, respec-
tively, with a mean survival of nine months in all patients. There were no signifi-
cant complications related to TACE. 
Conclusion: TACE produces an effective tumor response for targeted r-HCC
after LDLT. However, the survival rate of patients with r-HCC after LDLT is poor
due to extrahepatic metastasis and intrahepatic recurrence.
ne million patients worldwide suffer from hepatocellular carcinoma
(HCC) each year, accounting for approximately one million deaths
annually (1). In recent years, liver transplantation has become an
excellent treatment option for HCC patients because the procedure is able to cure the
tumor as well as the underlying cirrhosis. Furthermore, in an effort to bridge the gap
between the available organ supply and demand, living donor liver transplantation
(LDLT) has become an acceptable, alternative treatment option for patients with HCC
(2). 
However, significant HCC recurrence ranges from 15% to 69%, which is considered
treatment failure, in different series (3 6). The poor actuarial recurrence rates
reported with LDLT likely reflect the selection of patients with more advanced HCC
stages, rather than the hypothetical risk of recurrence related to neoplastic cell stimula-
tion by hepatic growth factors (7, 8). Surprisingly little is known about the natural
history, the therapeutic effect or the outcome of patients with cancer recurrence after
liver transplantation (9 11). This article describes the tumor response and survival
rate of patients after transcatheter arterial chemoembolization (TACE) treatment of
recurrent HCC (r-HCC) after LDLT. 
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MATERIALS AND METHODS
Patients
Between August 1992 and June 2005, 1,008 LDLTs
were performed and followed in our institution; patients
who died within three months of the procedure were
excluded from this study. Pathologic examination of
extracted cirrhotic liver revealed HCCs in 252 patients
(25.0%). During the follow-up period after LDLT, 42 of
these 252 patients (16.7%) were diagnosed with recurrent
HCC in the transplanted liver as well as in extrahepatic
organs such as lung or bone. 
TACE was indicated after LDLT for r-HCC with
intrahepatic or extrahepatic locations with feeding arteries
from the celiac trunk or right inferior phrenic artery or
intercostal artery. Contraindications were Child-Pugh class
C liver profile (n = 8), hyperbilirubinemia > 3 ng/ml (n =
6), and complete obstruction of the main portal vein (n =
3). TACE was performed in 28 of the 42 patients with r-
HCC. All 28 patients had unresectable r-HCC (n = 26) or
refused repeat surgery for resection of r-HCC (n = 2).
Written informed consent was obtained from the patients
and their family members. The patient demographics for
those included in the study are summarized in Table 1.
There were two female patients and 26 male patients, with
a mean age of 53.4 years (range, 38 65 years). LDLT was
performed in 28 patients as left lobe (n = 6), right lobe (n =
18), and dual LDLT from different donors (n = 4).
Radiological diagnostic imaging studies and elevation of
the alpha fetoprotein (AFP) values were used to establish
the r-HCC diagnosis; diagnostic imaging studies included
ultrasound (US), computed tomography (CT), and angiog-
raphy. CT of the chest, abdomen, and pelvis was
performed in each patient before TACE treatment to
detect extrahepatic disease. 
Tumors exceeded the Milan criteria in the explanted
liver in 153 of the 252 patients (60.7%) diagnosed with
HCC before LDLT and in 29 of the 42 patients (69.0%)
with recurrent HCC (12). Tumors in the explanted liver of
19 of the 28 study patients (67.9%) also exceeded the
Milan criteria.
Patterns of Recurrent Hepatoccellular Carcinoma
The characteristics of r-HCC are summarized in Table 2.
The median time from liver transplantation to detection of
r-HCC was 15 months (range, 2 57 months). TACE was
performed within one year, between one and three years,
between two and three years, or more than three years
after LDLT in 16 (57.1%), seven (25.0%), four (14.3%),
or one (3.6%) patient, respectively. Nine of 26 patients
with intrahepatic recurrence had solitary nodular r-HCC
(Fig. 1), while the remaining 17 patients had multiple r-
HCC (Fig. 2). Eighteen study patients (64.3%) were
initially diagnosed with r-HCC extrahepatic metastasis, of
which lung metastasis was the most common followed by
bone and peritoneal metastases (Table 2). AFP values were
greater than 400 ng/ml in 18 of 28 patients (64.3%).
Transcatheter Arterial Chemoembolization
The tumor size and number, the feeding arteries, and the
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Table 2. Characteristics of r-HCC after LDLT
Characteristics Patients (n = 28)
Period (months) from LDLT to recurrence 14.3 (2 57)
Extrahepatic metastasis 18 (64.3%)
Lung 16 (57.1%)
Bone 04 (14.3%)
Omentum and mesentery 04 (14.3%)
Intrahepatic recurrence 26 (92.9%)
Single 09 (32.1%)
Multiple 17 (60.8%)
Extrahepatic recurrence 2 (7.1%)
Alpha-fetoprotein (ng/ml)
400 10 (35.7%)
> 400 18 (64.3%)
Note. r-HCC = recurrent hepatocellular carcinoma; LDLT = living donor 
liver tranplantation
Table 1. Demographic Data of Study Patients Prior to LDLT
Patients (n = 28)
Age (years) 38 65 (mean, 53.4)
Transplanted lobe
Right 18
Left 6
Dual 4
TNM stage
I 3
II 12
III 12
IVb* 1
Milan criteria
Within 9
Beyond 19
Prior therapy
TACE 25
Cytoablation (RFA, PEI) 5
Liver resection 1
No prior therapy 2
Note. LDLT = living donor liver tranplantation; TACE = transcatheter 
arterial chemoembolization; RFA = radiofrequency ablation; PEI =
percutaneous ethanol injection
* Omental seeding was diagnosed only in pathology.
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Fig 1. A. Contrast-enhanced arterial-phase axial CT image of the
liver 17 months after living donor liver transplantation shows the
single arterial enhancing mass (arrow) in the posterior portion of
the transplanted liver. 
B. Arteriogram from the celiac trunk (late arterial phase) shows an
area of tumor blush in the transplanted liver (arrow).
C. Arteriogram from the celiac trunk immediately after embolization
shows that the tumor blush has disappeared. 
D. Contrast-enhanced arterial-phase axial CT image of the liver
one month after transcatheter arterial chemoembolization reveals
complete iodized oil accumulation (arrow) in the tumor. We
interpreted this patient as having CR. 
E. Contrast-enhanced arterial-phase axial CT image of the liver 22
months after transcatheter arterial chemoembolization shows a
decrease in the size of the recurrent hepatocellular carcinoma with
iodized oil accumulation.
E
degree of portal venous thrombosis were evaluated by
celiac and superior mesenteric angiography. TACE was
performed after a 3 Fr microcatheter (MicroFerret, Cook
Inc, Bloomington, IN) was advanced into the feeding
artery. In the first procedure, cisplatin (Cisplan, Dong-A,
Seosan, Korea) was infused into the hepatic artery for 15
minutes without embolic particle administration. A
mixture of iodized oil (Lipiodol, Laboratoire Guerbet,
Cedex, France) and cisplatin was then injected into the
feeding arteries followed by embolization with gelatin
sponge (Spongostan, Pharmacia and Upjohn, Kalamazoo,
MI); the infused dose of cisplatin was 2 mg/Kg of the
patient’s weight. The injected dose of iodized oil depended
on the tumor size, ranging from 1 to 10 ml (mean: 4.6 ml),
and the gelatin sponge consisted of cubes measuring 1 2
mm.
Transcatheter arterial chemoembolization was
performed in a lobar artery or a segmental artery in 26
patients with intrahepatic recurrence. TACE was
performed in the left gastric artery and in the right inferior
phrenic and right intercostal arteries in two patients with
extrahepatic recurrence. One of these two patients had an
extrahepatic r-HCC attached to the posterior portion of
the transplanted liver that was supplied by right inferior
phrenic and right intercostal arteries (Fig. 3). The other
patient had r-HCC in the posterior portion of the left
lateral segment of the transplanted liver that was supplied
by left gastric artery. The included patients underwent 1-5
cycles of TACE (mean, 2.5 cycles per patient) during the
follow-up period. 
Follow-up 
Tumor response was evaluated based on CT studies
performed 1 3 months after TACE and was classified into
five grades as follows: complete response (CR), total
disappearance of the tumor (Figs. 1, 3); partial response
(PR), reduction of 50% or more in maximum tumor size
on CT images; minimal response (MR), reduction of 25
50%; stable disease (SD), change of < 25% in tumor size;
and progressive disease (PD), increase of 25% or more in
tumor size (Fig. 2) (13). Tumor size was measured by
electronic calipers as the maximum perpendicular
diameters of each tumor (a, b). The following formula was
used to calculate the change in total tumor size:
Percentage change in tumor size = 100 * (a* b a’* b’)/
(a* b)
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Fig. 2. A. Contrast-enhanced delayed-phase axial CT image of a
transplanted liver six months after living donor liver transplantation,
with the left lobe showing multiple recurrent hepatocellular carcino-
mas in the entire transplanted liver; however, blood flow is preserved
in the portal vein. 
B. Arteriogram from the celiac trunk (late arterial phase) shows
multiple hypervascular tumors in the entire transplanted liver. 
C. Contrast-enhanced arterial-phase axial CT image of the
transplanted liver one month after transcatheter arterial chemoem-
bolization shows progression of the recurrent hepatocellular carcino-
mas in both size and number. Some nodules show partial accumula-
tion of iodized oil. We interpreted this patient as having progressive
disease.
C
where a* b represents the product of the longest perpen-
dicular diameters of each tumor before treatment, and a’*
b’ is the product of the tumor diameters after treatment.  
Changes in AFP values one month after TACE were also
evaluated in patients with abnormal AFP values at the
time of TACE. 
Statistical Analysis
The estimated survival rates were calculated using the
Kaplan-Meier method. 
RESULTS
Targeted lesion tumor response to TACE. 
The tumor response of the targeted lesion to TACE was
summarized in Table 3. Iodized oil accumulated in the
main tumor in all patients, but complete response
corresponding to total disappearance of the tumor was
only observed in three patients on follow-up CT (Figs. 1,
3). Although complete or partial response of the targeted
lesions to TACE was observed in 14 of 28 patients
(50.0%), 21 of these 28 patients (75.0%) had another r-
HCC during the 3-month follow-up period, and 26 of the
28 patients (92.9%) manifested another r-HCC in an
intrahepatic or extrahepatic location during the 6-month
follow-up period. Six of 28 patients experienced progres-
sive disease (increased tumor size) despite TACE
treatment. Two of three patients still living at the time of
writing have been in complete remission for 22 and eight
Ko et al.
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Fig 3. A. Contrast-enhanced delayed-phase axial CT image of the
liver after living donor liver transplantation reveals a small nodule in
the extrahepatic space of the transplanted liver (arrow). This patient
had an elevated alpha fetoprotein level at that time. 
B. Digital image of the intercostal and right inferior phrenic arteries
after transcatheter arterial chemoembolization shows subtle accumu-
lation of iodized oil (arrow). 
C. Contrast-enhanced arterial-phase axial CT image of a
transplanted liver one month after transcatheter arterial chemoem-
bolization shows completed accumulation of iodized oil in the nodule
(arrow). This patient’s alpha fetoprotein level decreased after
transcatheter arterial chemoembolization. 
C
Table 3. Targeted Lesion Tumor Response to TACE
Tumor Response No. (%)
Complete response 3 (10.7)
Partial response 11 (39.3)
Minimal response 5 (17.9)
Stable disease 3 (10.7)
Progressive disease 6 (21.4)
months, respectively, since the initial TACE therapy (Figs.
1, 3).
The AFP levels of eight of 18 patients with abnormal
baseline AFP levels (> 400 ng/ml) had decreased one
month after TACE. Ten of the 18 patients with elevated
AFP levels had another intrahepatic recurrence or progres-
sive extrahepatic recurrence. 
Overall, the TACE procedure was well tolerated by all
patients, and no major complications developed during
follow-up period. Five patients (17.9%) experienced some
immediate side effects after TACE, including transient
nausea, vomiting, diarrhea, hypertension, tachycardia, and
right upper quadrant pain, but these effects resolved within
a few days of the procedure. 
Survival
Survival was measured from the date of LDLT, r-HCC
diagnosis after LDLT, or TACE treatment until death or
until December 2005. At the time of this writing, 25
patients have died and three are still living. The causes of
deaths were pneumonia and sepsis (n = 18), hepatic failure
(n = 5), and organ failure due to extensive metastasis (n =
2). The actual 1-, 3-, and 5-year survival rates after LDLT
were 71.4%, 31.5%, and 6.0%, respectively (Fig. 4). The
estimated median survival after LDLT in the included
patients was 28 months (95% CI, 12.4 43.5 months). The
actual 1-, 3-, and 5-year survival rates after TACE for r-
HCC were 47.9%, 6.0%, and 0%, respectively (Fig. 5).
The estimated median survival after TACE for r-HCC was
nine months. 
DISCUSSION
Systemic chemotherapy, surgical resection and non-
surgical treatments, such as TACE and ablation, are
performed to treat r-HCC after LDLT (10). Few previous
studies have evaluated the tumor responses to various
treatment modalities in r-HCC after liver transplantation.
In particular, to our knowledge, there were no reports
regarding TACE treatment of r-HCC after LDLT.
However, the targeted lesion tumor response in the
present study was the same or more favorable compared
with other studies on HCC before transplantation. In many
previous studies, TACE achieved a partial response or
better in 15% 55% of patients with HCC before
transplantation (14 17). Ebied et al. studied 72 patients
with biopsy-proven, unresectable HCC and focused on 186
individual tumor masses. The patients were classified as
responders or non-responders based on CT evidence of
altered tumor size and tumor necrosis. Thirty-eight
patients (47.2%) were responders and 34 were non-
responders. In the present study, 28 patients with r-HCC
underwent TACE. A favorable tumor response in the
targeted lesion (partial response or better) was observed in
50% of patients after TACE. 
Nevertheless, favorable tumor response in the targeted
lesion did not reflect favorable survival, and the survival
rate in the present study was similar to other reports.
Recurrence of HCC after liver transplantation clearly has a
major impact on outcome. The five-year survival was
reported to be significantly lower for patients with
recurrence (22%) than for patients without recurrence
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Fig. 4. Overall cumulative survival curve of 28 patients with
recurrent hepatocellular carcinoma calculated from the time of
living donor liver transplantation.
Fig. 5. Cumulative survival curve of 28 patients with recurrent
hepatocellular carcinoma calculated from the time of recurrent
hepatocellular carcinoma diagnosis.
(64%) (p < 0.0001) (18); the median survival was around
nine months after the diagnosis of recurrence. Shorter time
to recurrence and the presence of bone metastases were
the main factors significantly associated with poorer
prognosis once recurrence manifested (18). In another
series, however, 18 of 57 patients with r-HCC underwent
potentially curative treatments such as surgical resection or
radiofrequency ablation. The five-year post-transplant
survival among these patients was 47% (10). This is consis-
tent with the 57% survival at four years reported
elsewhere for similar patients (9). However, it is impossible
to determine from these studies whether surgical treatment
of recurrence prolongs survival or whether patients who
are amenable to surgical treatment are a more favorable
group. In the present study, 26 of 28 patients had
unresectable r-HCC. The mean survival periods were 28
months overall and nine months after diagnosis of r-HCC.
And the actual 1-, 3-, and 5-year survival rates after LDLT
were 71.4%, 31.5%, and 6.0%, respectively, in this study.
These mean survival values were similar to or lower than
those of the studies mentioned previously. We believe that
this resulted from the inclusion of patients with advanced
and unresectable r-HCC at the time of r-HCC diagnosis, as
mentioned above. 
The small benefit to survival afforded by TACE, in spite
of favorable tumor response to targeted r-HCC, may be
caused by the aggressiveness of the tumor, which is
indicated by the high rate of extrahepatic recurrence and
rapid tumor recurrence in the remaining liver after initial
TACE treatment. Early reports suggested that the course of
recurrent HCC after transplant is more aggressive than
that of recurrence after hepatic resection, presumably due
to immune suppression (19). This has not been borne out
in subsequent studies, however (20). Nevertheless, the
drugs used to prevent transplant rejection have a variety of
effects that go beyond immune suppression (10). 
In this study, extrahepatic metastasis were observed in
18 of 28 (64.3%) included patients. In another study, 48 of
57 patients (84.2%) with r-HCC after liver transplantation
had extrahepatic metastases (18). These patterns of
metastases in patients with r-HCC after liver transplanta-
tion differ from those in patients with primary HCC
without liver transplantation. In one study, for example 65
patients (13.5%) had extrahepatic metastases among 482
patients who were diagnosed with HCC (14). There is no
standard treatment for extrahepatic metastases, and few
previous reports exist regarding its treatment (21). In the
study by Chung et al., 68 HCC patients with major portal
vein thrombosis (n = 47) or distant metastasis (n = 27)
were randomly allocated to groups with or without intra-
arterial Cisplatin infusion. The group receiving intra-
arterial Cisplatin infusion had a significantly higher 1-year
survival rate than the other group (22). We also performed
intra-arterial Cisplatin infusion before embolization with
iodized oil and gelatin sponge to treat intrahepatic r-HCC
as well as extrahepatic metastasis.
There are limitations of the present study. Most of the
included patients had extrahepatic recurrence as well as
intrahepatic recurrence, and systemic chemotherapy was
not controlled. A controlled study is needed for further
evaluation of TACE with regard to its effect on the
survival of patients with r-HCC after LDLT. 
In conclusion, TACE appears to produce an effective
tumor response in targeted r-HCC after LDLT. However,
survival of patients with r-HCC after LDLT is poor due to
extrahepatic metastasis and additional intrahepatic
recurrence.
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